Lantern Pharma Inc. (Nasdaq: LTRN)
Edit

Lantern Pharma Inc. (Nasdaq: LTRN)

http://www.lanternpharma.com/
Last activity: 01.09.2023
Tags:Artificial IntelligenceBioTechDataDevelopmentDrugHealthTechLearnMedtechPersonalPlatform
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology. Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.
Mentions
50
Location: United States, Texas, Dallas
Employees: 11-50
Total raised: $72.7M
Founded date: 2013
Twitter
LinkedIn
Youtube
Email

Investors 1

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
14.01.2021-$69M-prnewswire...
02.05.2017Series A$3.7M-hitconsult...

Mentions in press and media 50

DateTitleDescriptionSource
01.09.2023Daily AI Roundup: Biggest Machine Learning, Robotic And Auto...This is our AI Daily Roundup . We are covering the top updates from around the world. The updates wi...aithority....
31.08.2023Lantern Pharma Expands AI Capabilities of RADR Platform to A...Expansion of RADR platform adds new AI capabilities for the automated identification of new and effe...aithority....
12.06.2023Lantern Pharma Receives FDA Clearance of IND Application for...Lantern Pharma, an artificial intelligence (“AI”) company developing targeted and transformative can...aithority....
09.06.2023Lantern Pharma Leverages AI Platform, RADR, to Develop Break...Lantern will leverage its proprietary AI platform, RADR, to rapidly develop novel cryptophycin-antib...aithority....
06.03.2023Lantern Pharma Announces Formation of Starlight Therapeutics...Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR artificial int...aithority....
15.02.2023Lantern Pharma Further Enhances Capabilities of its AI Drug ...Lantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR artificial int...aithority....
11.10.2022Lantern Pharma to Present at The MicroCap Rodeo Presents The...DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage bio...accesswire...
24.01.2022Lantern Pharma Receives Rare Pediatric Disease and Orpan Dru...DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceuti...marketscre...
18.01.2022Lantern Pharma Announces Collaboration & Research Agreem...DALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceuti...marketscre...
12.01.2022Lantern Pharma Expands Precision Oncology Collaboration with...DALLAS, Jan. 12, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceuti...marketscre...
Show more